Categories: Market

Dr Reddy’s launches Clofarabine in the US Market

Mumbai, November 28, 2017: Pharma major Dr Reddy’s Laboratories Ltd said that it has launched Clofarabine injection, a therapeutic and generic equivalent of Clolar injection of Genzyme Corporation, in the US market, approved by the USFDA.
The Clolar brand and generic had the US sales of approximately USD53 million for the most recent 12 months ended September 2017 as per IMS Health,company said in afiling with BSE. The drug is indicated for treating a particular type of cancer, among other prescribed use.
Dr Reddy Laboraties Clofarabine injection is avaliable in single-dose, 20 mL fints vials contaning 20 mg of Clofarabine in 20 mL of solution.(1mg/mL).

United News Of India

The Pharma Times News Bureau

Recent Posts

DKMS-BMST – Bridging the Care Gap in Blood Cancer Treatment on National Cancer Awareness Day

New Delhi, November 07, 2024: National Cancer Awareness Day serves as a poignant reminder of…

11 hours ago

The Arya Vaidya Pharmacy (Coimbatore) Ltd. Strengthens Legacy with New Initiatives and Expanded Product Portfolio

Coimbatore, November 07, 2024: The Arya Vaidya Pharmacy (Coimbatore) Ltd. (AVP), a pioneer in Ayurvedic…

11 hours ago

New medical nutrition ingredient combines high-protein with “best taste yet”

New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…

1 day ago

6 Early Signs of Ovarian Cancer

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

1 day ago

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

2 days ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

3 days ago